Ribo's Overseas R&D Team and Investors Visited China to Strengthen Global R&D Synergy
October 16, 2026 – Suzhou & Beijing China
Recently, the R&D team from Ribocure Pharmaceuticals AB ("Ribocure"), the overseas subsidiary of Suzhou Ribo Life Science (06938.HK, "Ribo" or "the Company"), visited Ribo's Kunshan headquarters and its Beijing R&D center, where they engaged in in-depth discussions with the Chinese team on clinical project development and progress, innovative technologies, business development and cross-regional collaboration. Mr. Erik Selin, a director and core investor of Ribocure, and also a cornerstone investor of Ribo, joined the visit, gaining firsthand insight into the Company's R&D activities and collaboration between Chinese and Swedish teams.
Ribo Team and Swedish investor Erik Selin
This visit takes place at a time when the Company's core pipeline in anticoagulation field has made significant progress, and multiple Phase II/IIb clinical trials have been approved in Europe. As the global clinical and business development center of Ribo, Ribocure leverages its team's extensive experiences to collaborate with its Chinese counterparts in advancing the global development and international cooperation of siRNA drugs. The successive achievement of clinical milestones has further validated the remarkable success of Ribo's global R&D strategy anchored at Ribocure.
In 2025, Mr. Erik Selin led the $33 million equity financing of Ribocure and joined the board of directors following the completion of the financing. This visit to the Kunshan headquarter and the Beijing R&D center provided him with the opportunity to obtain further understanding of Ribo's R&D platforms and program progresses, as well as to engage in thorough discussions with teams from various locations. During the visit, Mr. Erik Selin and other investors offered recommendations on the teamwork collaboration between China and Sweden, and shared their insights on overseas capital markets and the development of the global siRNA sector.
As the Company's pipeline progresses into increasingly advanced clinical stages, the alignment between technological research, clinical operation and international collaboration has become increasingly critical. This face-to-face communication has laid the groundwork for the team and investors to reach a consensus on the global development of siRNA-based drugs and establish long-term collaboration.
About Suzhou Ribo Life Science Co. Ltd. and Ribocure Pharmaceuticals AB
Suzhou Ribo Life Science Co. Ltd. (Ribo, 06938.HK) is a global biopharmaceutical company dedicated in the development and commercialization of small interfering RNA (siRNA)-based therapeutics. Driven by its vertically integrated technology platforms, Ribo has built a strong and differentiated product pipeline targeting major disease areas including cardiovascular and metabolic disorders, liver and kidney diseases etc. Through continuous innovation, Ribo is committed to delivering revolutionary siRNA treatment solutions to patients worldwide. For more information, please visit www.ribolia.com.
As an overseas subsidiary of Suzhou Ribo Life Science, Ribocure Pharmaceuticals AB (Ribocure) is dedicated to globalized development of life-saving oligonucleotide therapies, with focus on development of assets and pipeline as well as new target ideas and on building innovative capacities to conduct clinical trials and developing siRNA drugs to address real unmet medical needs globally. For more information, please visit www.ribocure.com.